Product Description
Mechanisms of Action: Angiogenesis Inhibitor, METAP2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: France
Approved Indications: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2017-001532-19 |
2017-001532-19 | P3 |
Active, not recruiting |
Asthma |
2021-03-11 |
50% |
2022-03-13 |
Treatments |
